For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Biotheryx, Inc.

USPTO Granted Patents = 36

CIPO Patents = 12

EPO Patents = 2

Trademarks = 3

Forward Citations = 58

Loading Chart...

Loading Chart...

39 inventors (with patents filed for the assignee):

Kyle W H Chan (33 out of 47 patents)

Frank Mercurio (32 out of 47 patents)

Leah M Fung (27 out of 35 patents)

4. Robert W Sullivan (26 out of 56 patents)

5. Paul E Erdman (22 out of 36 patents)

6. Eduardo Torres (13 out of 95 patents)

7. Aparajita Hoskote Chourasia (9 out of 9 patents)

8. Imelda Lam (4 out of 4 patents)

9. Armen Manoukian (4 out of 6 patents)

10. Sam Scanga (4 out of 6 patents)

11. Fabrizio Mastronardi (4 out of 7 patents)

12. David I Stirling (3 out of 43 patents)

13. Joseph P Vacca (3 out of 109 patents)

14. David Aaron Hecht (2 out of 2 patents)

15. Dansu Li (2 out of 36 patents)

36 patents: Sort by Forward Citations

1. 12419962 - Quinazolines, pharmaceutical compositions, and therapeutic applications (2025-09-23),

2. 11400084 - Aminoamide compounds (2022-08-02),

3. 11352338 - Substituted isoindolinones (2022-06-07),

4. 11345714 - Compounds targeting proteins, compositions, methods, and uses thereof (2022-05-31),

5. 11345712 - Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications (2022-05-31),

6. 11236105 - Bicyclic compounds and methods of use (2022-02-01),

7. 11236103 - Bifunctional compounds (2022-02-01),

8. 11191769 - Fused thiophene compounds (2021-12-07),

9. 11072599 - Pyrazole compounds and uses thereof (2021-07-27),

10. 10960003 - Pyrazole pyrimidine derivative and uses thereof (2021-03-30),

11. 10927104 - Ether compounds and uses thereof (2021-02-23),

12. 10905684 - Aminoamide compounds (2021-02-02),

13. 10889593 - Compounds targeting proteins, compositions, methods, and uses thereof (2021-01-12),

14. 10857155 - Compounds targeting proteins, compositions, methods, and uses thereof (2020-12-08),

15. 10844039 - Substituted isoindolinones (2020-11-24),

BioTheryX is a biopharmaceutical company focused on the development and commercialization of innovative targeted therapies for cancer treatment. With a strong emphasis on precision medicine, their mission is to improve patient outcomes by delivering highly effective and safe therapies that specifically target the underlying mechanisms of cancer progression. BioTheryX has a diverse portfolio of novel drug candidates that are designed to address unmet medical needs and offer new treatment options for patients. Through rigorous research and strategic collaborations, they strive to advance the field of oncology and provide hope to patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

36 Patents

#161 in San Diego, CA

#2,176 in California

#9,183 in US

#18,155 in the World

San Diego, CA, United States of America

Biotheryx, Inc.

Forward Citations = 58

39 inventors:

Kyle W H Chan (33 out of 47 patents)

Frank Mercurio (32 out of 47 patents)

Leah M Fung (27 out of 35 patents)

4. Robert W Sullivan (26 out of 56 patents)

5. Paul E Erdman (22 out of 36 patents)

Please report any incorrect information to support@idiyas.com

Loading…